Phuoc T Tran MDProfessor, Radiation Oncology and Molecular Radiation Sciences, Oncology and Urology, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland
Phuoc T. Tran, MD, PhD, is a Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University. He is co-Director of the Program in Cancer Invasion and Metastasis in the Sidney Kimmel Comprehensive Cancer Center and has co-appointments in Medical Oncology, the James Buchanan Brady Urological Institute and the Cellular and Molecular Medicine Program. Phuoc is a board-certified radiation oncologist and clinically specializes in treatment of genitourinary (GU) malignancies. His research program has been continuously funded by the NIH-DoD and foundations for a decade to focus on tumor cell epithelial plasticity programs and novel agents to enhance the local and systemic effects of radiation. He also leads an active clinical trials program that includes interventional and translational investigator-initiated studies. He is currently the PI of the first investigator initiated clinical trial examining the next generation AR-antagonist enzalutamide as a radiosensitizer for men with biochemical failure following surgery - SALV-ENZA. He is the NRG Oncology GU Translational Science chair, RSNA R&E Nominating Committee Member at Large, ASTRO Science Council Research Grants Subcommittee chair and a NCI RTB study section member.
Phuoc received his undergraduate degree at UCSD and his MD and PhD degrees at Oregon Health and Science University. He then completed radiation oncology residency and postdoctoral fellowship at Stanford. Phuoc’s graduate and postdoctoral work focused on DNA repair, cancer biology, and transgenic mouse models. He subsequently joined the faculty of Johns Hopkins University where he served as Clinical Director from 2015-2017 in the department of Radiation Oncology and Molecular Radiation Sciences . He has received numerous awards for his research and clinical work from the RSNA, ASTRO, the Sidney Kimmel Foundation, the American Cancer Society, Uniting Against Lung Cancer, American Lung Association, the Movember Foundation, the Prostate Cancer Foundation and was voted a Top Doctor in Baltimore Magazine. He also serves as a Senior Editor/Editorial Board member for Cancer Research and the Journal of Clinical Oncology.
DisclosuresDr. Tran discloses the following:
- RefleXion Medical Inc & Noxopharm
- Natsar Pharm
- Astellas Pharm, Bayer Healthcare, Asclepix Therapeutics, & RefleXion Medical Inc
- NIH (U01CA212007, U01CA231776 & R21CA223403)
- PCF, Movember, Nesbitt-McMaster Foundation, Ronald Rose & Joan Lazar, Barabara’s Fund, National Capitol Cancer Research Fund
Recent Contributions to PracticeUpdate:
- Stereotactic Radiotherapy for Prostate Bed Recurrence After Prostatectomy
- Impact of Postoperative Radiotherapy in Men With Persistently Elevated PSA After Radical Prostatectomy
- Effect of Radium-223 Dichloride on Hospitalization for Symptomatic Prostate Cancer Patients
- Prospective Phase 2 Trial of Once-Weekly Hypofractionated Radiation Therapy for Low-Risk Adenocarcinoma of the Prostate